
CAI (CAI) Stock Forecast & Price Target
CAI (CAI) Analyst Ratings
Bulls say
Caris Life Sciences is a patient-centric, next-generation AI TechBio company with a strong growth outlook. The company has guided to a positive financial forecast, with expected revenue growth of 23-26% and profitability by 2026. With a solid financial position, a market-leading position in tissue-based CGP testing, and a growing portfolio of products, Caris is well-positioned to capitalize on the rapidly-growing precision oncology market.
Bears say
Caris Life Sciences is a high-risk investment due to its uncertain profitability and significant losses since inception, as well as the potential for substantial indebtedness and the need to raise additional capital. While the company has shown strong operational performance, especially with its recent ASP expansion, there are risks in terms of valuation and competition in the precision oncology space. Additionally, the success of newer tests, such as Caris Detect, remains uncertain and may require the company to continue conserving cash until alternative funding can be arranged.
This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.
CAI (CAI) Analyst Forecast & Price Prediction
Start investing in CAI (CAI)
Order type
Buy in
Order amount
Est. shares
0 shares